Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MTX-474

Phase 2Biologic

MMediar Therapeutics

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Cutaneous Systemic SclerosisRecruiting

Diffuse Cutaneous Systemic SclerosisPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Diffuse Cutaneous Systemic Sclerosis

NCT07287670

Clinical

Trials by Indication[1]

Trial1 trial

A First-in-Human Safety Trial of MTX-474

Completed·MMediar Therapeutics·Phase 1·NCT06535841·78 enrolled

Diffuse Cutaneous Systemic Sclerosis1 trial

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Recruiting·MMediar Therapeutics·Phase 2·NCT07287670·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MTX-474. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MTX-474 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MTX-474. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mediar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMediar Therapeutics

Related News